title: Quantitative proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes.
abstract: A quantitative proteomics analysis of the macular Bruch membrane/choroid complex was pursued for insights into the molecular mechanisms of age-related macular degeneration (AMD). Protein in trephine samples from the macular region of 10 early/mid-stage dry AMD, six advanced dry AMD, eight wet AMD, and 25 normal control post-mortem eyes was analyzed by LC MS/MS iTRAQ (isobaric tags for relative and absolute quantitation) technology. A total of 901 proteins was quantified, including 556 proteins from > or =3 AMD samples. Most proteins differed little in amount between AMD and control samples and therefore reflect the proteome of normal macular tissues of average age 81. A total of 56 proteins were found to be elevated and 43 were found to be reduced in AMD tissues relative to controls. Analysis by category of disease progression revealed up to 16 proteins elevated or decreased in each category. About 60% of the elevated proteins are involved in immune response and host defense, including many complement proteins and damage-associated molecular pattern proteins such as alpha-defensins 1-3, protein S100s, crystallins, histones, and galectin-3. Four retinoid processing proteins were elevated only in early/mid-stage AMD, supporting a role for retinoids in AMD initiation. Proteins uniquely decreased in early/mid-stage AMD implicate hematologic malfunctions and weakened extracellular matrix integrity and cellular interactions. Galectin-3, a receptor for advanced glycation end products, was the most significantly elevated protein in advanced dry AMD, supporting a role for advanced glycation end products in dry AMD progression. The results endorse inflammatory processes in both early and advanced AMD pathology, implicate different pathways of progression to advanced dry and wet AMD, and provide a new database for hypothesis-driven and discovery-based studies of AMD.
authors.affiliation: Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
authors.forename: Xianglin
authors.initials: X
authors.lastname: Yuan
authors.forename: Xiaorong
authors.initials: X
authors.lastname: Gu
authors.forename: John S
authors.initials: JS
authors.lastname: Crabb
authors.forename: Xiuzhen
authors.initials: X
authors.lastname: Yue
authors.forename: Karen
authors.initials: K
authors.lastname: Shadrach
authors.forename: Joe G
authors.initials: JG
authors.lastname: Hollyfield
authors.forename: John W
authors.initials: JW
authors.lastname: Crabb
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015153:Blotting, Western; D016570:Bruch Membrane / Q000166:cytology / Q000378:metabolism* / Q000473:pathology*; D018450:Disease Progression; D005136:Eye Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000145:classification / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D020543:Proteome / Q000378:metabolism; D040901:Proteomics / Q000379:methods*
chemical_list: D005136:Eye Proteins; D020543:Proteome